Nebenwirkungen · Briviact (in Italy: Nubriveo)
Briviact 10 mg/ml oral solution · Abschnitt 4.8 · PDF-Seite 29
HOS-132779 · Präparat HOS-097290
In the table below, adverse reactions, which were identified based on review of the three placebo- controlled, fixed-dose studies safety database in subjects ≥ 16 years of age and from post-marketing experience, are listed by System Organ Class and frequency. The frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) and not known (frequency cannot be estimated from available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-19T16:24:00Z · SHA-256 8b43e201402e087df36cd28aad896b8b68dd1973b788cdf0991029210330f8cc · Passage 676d0ac2ab79fdad84ea1b95a765b1803e2b08e383ffce3a4ea78682999b5679 · Zeichen 698–1248 im Abschnitt